Revolution Medicines, Inc. Investment Income, Interest
Revolution Medicines, Inc. (RVMD) reported Investment Income, Interest of $35.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Revolution Medicines, Inc. investment income, interest for the quarter ending 2026-06-30 was $35.58M, a 58.81% increase year-over-year.
- Revolution Medicines, Inc. investment income, interest for the quarter ending 2026-03-31 was $19.51M, a 21.70% decline year-over-year.
- Revolution Medicines, Inc. investment income, interest for the quarter ending 2025-12-31 was $21.29M, a 0.32% increase year-over-year.
- Revolution Medicines, Inc. investment income, interest for the quarter ending 2025-09-30 was $22.08M, a 8.19% increase year-over-year.
- Revolution Medicines, Inc. investment income, interest for fiscal 2025 was $90.69M, a 4.39% increase from fiscal 2024.
- Revolution Medicines, Inc. investment income, interest for fiscal 2024 was $86.88M, a 82.98% increase from fiscal 2023.
- Revolution Medicines, Inc. investment income, interest for fiscal 2023 was $47.48M, a 418.70% increase from fiscal 2022.
- Revolution Medicines, Inc. investment income, interest for fiscal 2022 was $9.15M, a 885.36% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.58M 10-Q · filed 2026-08-05 | $55.09M 10-Q · filed 2026-08-05 | $76.38M derived: sum of 3 quarters · filed 2026-08-05 | $98.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $19.51M 10-Q · filed 2026-05-06 | $40.80M derived: sum of 2 quarters · filed 2026-05-06 | $62.88M derived: sum of 3 quarters · filed 2026-05-06 | $85.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $21.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $43.38M derived: sum of 2 quarters · filed 2026-02-25 | $65.78M derived: sum of 3 quarters · filed 2026-08-05 | $90.69M 10-K · filed 2026-02-25 |
| 2025-09-30 | $22.08M 10-Q · filed 2025-11-05 | $44.49M derived: sum of 2 quarters · filed 2026-08-05 | $69.40M 10-Q · filed 2025-11-05 | $90.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $22.40M 10-Q · filed 2026-08-05 | $47.32M 10-Q · filed 2026-08-05 | $68.54M derived: sum of 3 quarters · filed 2026-08-05 | $88.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $24.91M 10-Q · filed 2026-05-06 | $46.14M derived: sum of 2 quarters · filed 2026-05-06 | $66.55M derived: sum of 3 quarters · filed 2026-05-06 | $88.04M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $21.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $41.64M derived: sum of 2 quarters · filed 2026-02-25 | $63.12M derived: sum of 3 quarters · filed 2026-02-25 | $86.88M 10-K · filed 2026-02-25 |
| 2024-09-30 | $20.41M 10-Q · filed 2025-11-05 | $41.90M derived: sum of 2 quarters · filed 2025-11-05 | $65.66M 10-Q · filed 2025-11-05 | $84.64M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $21.49M 10-Q · filed 2025-08-06 | $45.25M 10-Q · filed 2025-08-06 | $64.22M derived: sum of 3 quarters · filed 2026-02-25 | $75.17M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $23.76M 10-Q · filed 2025-05-07 | $42.74M derived: sum of 2 quarters · filed 2026-02-25 | $53.68M derived: sum of 3 quarters · filed 2026-02-25 | $64.18M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $18.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $29.92M derived: sum of 2 quarters · filed 2026-02-25 | $40.42M derived: sum of 3 quarters · filed 2026-02-25 | $47.48M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.95M 10-Q · filed 2024-11-06 | $21.45M derived: sum of 2 quarters · filed 2024-11-06 | $28.50M 10-Q · filed 2024-11-06 | $33.58M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $10.50M 10-Q · filed 2024-08-07 | $17.56M 10-Q · filed 2024-08-07 | $22.64M derived: sum of 3 quarters · filed 2025-02-26 | $25.54M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $7.06M 10-Q · filed 2024-05-08 | $12.14M derived: sum of 2 quarters · filed 2025-02-26 | $15.04M derived: sum of 3 quarters · filed 2025-02-26 | $15.91M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $7.98M derived: sum of 2 quarters · filed 2025-02-26 | $8.85M derived: sum of 3 quarters · filed 2025-02-26 | $9.15M 10-K · filed 2025-02-26 |
| 2022-09-30 | $2.91M 10-Q · filed 2023-11-06 | $3.77M derived: sum of 2 quarters · filed 2023-11-06 | $4.08M 10-Q · filed 2023-11-06 | $4.31M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $867.00K 10-Q · filed 2023-08-08 | $1.17M 10-Q · filed 2023-08-08 | $1.41M derived: sum of 3 quarters · filed 2024-02-26 | $1.63M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $302.00K 10-Q · filed 2023-05-08 | $539.00K derived: sum of 2 quarters · filed 2024-02-26 | $762.00K derived: sum of 3 quarters · filed 2024-02-26 | $998.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $460.00K derived: sum of 2 quarters · filed 2024-02-26 | $696.00K derived: sum of 3 quarters · filed 2024-02-26 | $929.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | $223.00K 10-Q · filed 2022-11-07 | $459.00K derived: sum of 2 quarters · filed 2022-11-07 | $692.00K 10-Q · filed 2022-11-07 | $944.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $236.00K 10-Q · filed 2022-08-09 | $469.00K 10-Q · filed 2022-08-09 | $721.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $233.00K 10-Q · filed 2022-05-09 | $485.00K derived: sum of 2 quarters · filed 2023-02-27 | $832.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.56M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $599.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.33M derived: sum of 3 quarters · filed 2023-02-27 | $2.24M 10-K · filed 2023-02-27 |
| 2020-09-30 | $347.00K 10-Q · filed 2021-11-10 | $1.08M derived: sum of 2 quarters · filed 2021-11-10 | $1.99M 10-Q · filed 2021-11-10 | $2.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $730.00K 10-Q · filed 2021-08-11 | $1.64M 10-Q · filed 2021-08-11 | $2.26M derived: sum of 3 quarters · filed 2022-02-28 | $3.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $909.00K 10-Q · filed 2021-05-10 | $1.53M derived: sum of 2 quarters · filed 2022-02-28 | $2.29M derived: sum of 3 quarters · filed 2022-02-28 | $2.76M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $618.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.38M derived: sum of 2 quarters · filed 2022-02-28 | $1.85M derived: sum of 3 quarters · filed 2022-02-28 | $2.19M 10-K · filed 2022-02-28 |
| 2019-09-30 | $766.00K 10-Q · filed 2020-11-12 | $1.24M derived: sum of 2 quarters · filed 2020-11-12 | $1.57M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $470.00K 10-Q · filed 2020-08-10 | $805.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $335.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $777.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |